Breast cancer with a germline BRCA1/2 mutation (gBRCAm) is sensitive to DNA-damaging therapies, such as platinum therapies and poly (ADP-ribose) polymerase (PARP) inhibitors. Here, PARP1 is linked to breast carcinoma.